The most accurate formats for measurement of progesterone in clinical samples are competition and/or inhibition assays since the molecule is only 314 daltons. Progesterone in a clinical sample competes with a carefully chosen conjugated progesterone reagent for available binding sites on a capture antibody specific for progesterone. The signal seen in a competitive immunoassay is inversely proportional to the amount of progesterone present in a sample.

Progesterone Molecular Structure and Numbering of Positions

  MAB234P – Generated using progesterone-6-KLH immunogen

MAB235P – Generated using progesterone-11-KLH immunogen

A successful, specific clinical progesterone competition assay is dependent on the optimized pairing of a competition progesterone reagent with the anti-progesterone antibody. It is critical to understand the compatibility of the competition reagents used. Knowing the attachment point used in the chosen progesterone conjugate is important, as steric interactions can play a role in confounding an assay if the epitopes on the conjugate are blocked by the attached detection enzyme. The conjugation ratio used to develop the progesterone competition reagent can also have an effect on assay sensitivity and should be considered.

For the validation of MAB234P and MAB235P as capture antibodies, MBS used internally developed competition progesterone conjugates in a series of competitive ELISAs to look at antibody sensitivity and specificity. A limited supply of those progesterone conjugates are available for sampling with MAB234P and 235P while supplies last. MBS R&D assays demonstrated sensitivity levels within the normal clinical range for detection of progesterone.

Amid a wave of acquisitions and outsourced manufacturing by antibody service providers, MBS wants to reassure our customers that they can count on the stability and longevity of our organization.  MBS has been privately owned and operated in New England since 1990.  We have stayed true to our core proficiency and quality standards in antibody development, while continuously striving to add to our expertise and tools to assure the highest quality project outcomes.  

The cornerstones of our success have always been customer communication and in-house project management.  In 2013, MBS plans to add electrofusion to our hybridoma development services which also include innovative purification protocols and Octet kinetic analysis.  Investing in our technical capabilities to meet evolving customer needs signals our commitment to remaining your partner in antibody development well into the future.  

Browse our site to learn more about the cGMP antibody services offered by MBS:

Custom Monoclonal Antibody Development

Interaction Analysis via Octet

                               Prototype Assay Development

                                                                                           Polyclonal Antibody Development and Affinity Purification

                                                                                           Ascites and In Vitro Antibody Production

                                                                                           Optimized Antibody Purification

                                                                                           Antibody Characterization Services

                                                                                           Growing Catalog of MBS Produced Antibodies

The antibodies were evaluated for their ability to work as matched pairs in a mono-mono sandwich ELISA format. Biotin conjugates of both antibodies were prepared for use as tracers. The antibodies demonstrated the ability to work in both capture/tracer configurations.

Both monoclonal antibodies were evaluated by indirect ELISA and sandwich ELISA (data not shown) for cross-reactivity to transferrin, both Apo (iron-free) and Holo (iron-saturated) forms.  The results suggest that neither antibody cross-reacts with transferrin to a significant degree.

Maltose Binding Protein (MBP) tags have demonstrated utility to increase expression and proper folding of proteins expressed in bacteria leading to improved solubility of the partner protein.

Maine Biotechnology Services Inc has developed a monoclonal antibody specific for Maltose Binding Protein (MBP) to optimize detection and purification of recombinant proteins utilizing MBP tags. MAB231P has been confirmed by Western Blot and ELISA to recognize MBP irrespective of the vector used for expression.  

Data

Several recent publications bring to light the superior performance of maltose binding protein in a variety of applications including, the ability of MBP to improve soluble expression₍₁₎, act as a carrier  and delivery system for fused proteins to target antigens₍₂₎, increasing the solubility of drug candidates₍₃₎, and even experimental therapeutic uses₍₄₎.

MBP References:

1.The ability to enhance the solubility of its fusion partners is an intrinsic property
of maltose-binding protein but their folding is either spontaneous or chaperone-mediated.
Raran-Kurussi S, Waugh DS.

2. Maltose-binding protein is a potential carrier for
oral immunizations, Veterinary Immunology and Immunopathology, 
P.Bellot,P.Tiels, V.Melkebeek, B.Devriendt, B.M.Goddeeris, E. Cox,

3. A chromatography-focused bioprocess that eliminates soluble aggregation
for bioactive production of a new antimicrobial peptide candidate, 
Xiang Li, Susanna Su Jan Leong, 

4. Synergistic antitumor effects of Escherichia coli maltose
binding protein and Bacillus Calmette–Guerin in a mouse lung carcinoma model
Qingyong Zhang, Weihua Ni, Xiaoxia Zhao, Fengli Wang, Zhuo Gao, Guixiang Tai,

His-tag Antibody

Data

MBS developed a mouse monoclonal antibody against a polyhistidine (His) tag. MAB230P shows
high affinity, excellent functionality by Western Blot, and the ability to bind to both N and C terminal
His-tags. MAB230P, has demonstrated apparent affinity of 8.85 x 10-12 with ability to detect His tagged antigen at
picolmolar concentrations. (Determined by Forte Bio Octet Red.)

                               1. MW Standard
                               2. N-term 6X-HIS TAG protein 100ng
                               3. N-term 6X-HIS TAG protein 25 ng
                               4. N-term 6X-HIS TAG protein 5 ng
                               5. MW Standard
                               6. C-term 6X-HIS TAG protein 100 ng
                               7. C-term 6X-HIS TAG protein 25 ng
                               8. C-term 6X-HIS TAG protein 5 ng

Included in the service will be the development of an optimized ELISA using your predicted matrices, transfer of protocols, and training support; making our lab an extension of yours.

Learn More

Order Samples Today

• Custom Project Design and Expert Analysis
• Project Start within 1 Week of Antigen Receipt
• In Process Samples Available
• Rapid Immunization
• MultiPure Discovery Scale Purification
• Octet Red Affinity Determination
• ReadyPure Development Scale Purification
• Cell Line Development in Just 4 Months
• In House Purification, Production, and Characterization

With 1 in 4 new hybridoma development projects having an anti-id goal and many being used by our pharmaceutical customers  in active clinical trials, MBS is proud to convey a high level of confidence to customers for these crucial, time sensitive programs. 

Contact us for a custom quote today.

Maine Biotechnology Services developed a comprehensive panel of antibodies specific for human Norovirus, including GII.4 2012 Sydney strain.  MAB223P through MAB228P have been tested across a broad range of strains, as reported in the table below.  In addition to being broadly cross reactive to GII.4 genotypes, MAB227P has demonstrated the ability to block ligand binding in surrogate neutralization assays.  MAB228P, developed against GI.1 1968 virus like particles (VLPs), has been shown to recognize additional GI types.  There are currently five known genogroups, of which three cause human disease: GI, GII, and GIV.  According to the CDC, since 2002 GII.4 has been the most common cause of Norovirus outbreaks.  

Datasheets for all New Norovirus Antibodies

MAB223P Norovirus GII
MAB224P Norovirus GII
MAB225P Norovirus GII
MAB226P Norovirus GII
MAB227P Norovirus GII (Blocking)
MAB228P Norovirus GI

Contact us to reserve your sample today. 

MAB223P-MAB227P, recently developed by MBS to recognize GII.4 strains of human Norovirus, (including GII.4 2012 Sydney) are featured in a new publication from our collaborators at the University of North Carolina titled,“Norovirus GII.4 Strain Emergence Correlates with Changes in Evolving Blockade Epitopes.”  MAB223P-MAB227P were developed in house by MBS R&D and are currently available for sampling. 

Secondary Antibodies

Secondary antibodies bind to the primary antibody to assist in detection, classification and isolation of target antigens. To ensure detection, the secondary antibody must be specific for the antibody species and isotype of the primary antibody in the application.

Currently we are offering secondary anti-human antibodies to: Fc, IgA, IgM, IgG1, IgG2, IgG3, IgG4, Kappa, and Lambda isotypes.

Isotype Control Antibodies

 Selecting a functional  isotype control is a critical step in many laboratory experiments, particularly flow cytometry and immunohistochemistry. The ideal isotype control has no specificity to the target cells within the assay, and adequately measures the level of non-specific background signal caused by primary antibodies.  Inquire today about MBS murine isotype control antibodies.

 Contact Us For Sampling Information